Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults with Moderate to Very Severe COPD

Trial Identifier: PT003016-00
Sponsor: Pearl Therapeutics, Inc.
NCTID:: NCT02268396
Start Date: November 2014
Primary Completion Date: January 2015
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
United States, FL Clearwater, FL, United States
United States, FL Tampa, FL, United States
United States, FL Winter Park, FL, United States
United States, NC Charlotte, NC, United States
United States, OH Columbus, OH, United States
United States, OR Medford, OR, United States
United States, SC Greenville, SC, United States
United States, SC Rock Hill, SC, United States
United States, SC Spartanburg, SC, United States
United States, VA Richmond, VA, United States